Skip to content
OpenCapital
Get started

United Therapeutics UTHR Orenitram — Cost of Sales

Other product segments

Tyvaso DPI
$83.2M+73.0%
Remodulin
$16.1M+16.7%
Nebulized Tyvaso
$8.6M+1.2%
Unituxin
$5M-3.8%
Adcirca
$1M-61.5%

Similar metrics at other companies

Ardelyx logo
ARDXProduct sales, net — Cost of Sales
$2.88M+22.9%
PBH
PBHNorth American OTC Healthcare — Cost of Sales
$113.17M+5.3%
Mirum Pharmaceuticals, Inc. logo
MIRMCost of Sales
$28.81M+25.1%
Syndax Pharmaceuticals logo
SNDXCost Of Product Sales
$2.63M+198%
Travere Therapeutics, Inc. logo
TVTXTotal net product sales — Cost of goods sold
$1.95M+55.6%
Kura Oncology logo
KURAProduct — Cost Of Product Sales
$14.25K—

Other financials

Income statement

See full
Revenue$781.5M-1.6%
Gross profit$648.1M-7.7%
Operating income$325.8M-14.9%
Net income$274.9M-14.7%
EPS (diluted)$5.82-12.2%

Balance sheet

See full
Cash & equivalents$1.3B-32.6%
Total debt$12.2M—
Total equity$5.9B-13.3%
Total assets$6.7B-13.3%

Cash flow

See full
Operating cash flow$463.3M+0.5%
CapEx$100.8M+34.6%
Free cash flow$362.5M-6.2%

Valuation

See full
Market cap$23B+84.1%
P/E17.9×+7.8×
P/S7.3×+3.2×

Profitability

See full
Gross margin86.6%-2.4pp
Operating margin45.3%-1.6pp
Net margin40.6%+0.2pp
FCF margin32.1%-5.6pp

Returns & leverage

See full
Return on equity20.3%+0.3pp
Debt / equity0×—
Current ratio4.8×-0.7×

Where this comes from

Reported directly by United Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.

The official record: United Therapeutics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about United Therapeutics's orenitram — cost of sales.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is United Therapeutics's orenitram — cost of sales?
United Therapeutics (UTHR) reported orenitram — cost of sales of $7.4M in Q1 2026.
How has United Therapeutics's orenitram — cost of sales changed year-over-year?
United Therapeutics's orenitram — cost of sales decreased by 10.8% year-over-year, from $8.3M to $7.4M.
What is the long-term trend for United Therapeutics's orenitram — cost of sales?
Over 4 years (2021 to 2025), United Therapeutics's orenitram — cost of sales has grown at a 9.9% compound annual growth rate (CAGR), from $19.7M to $28.7M.
What does orenitram — cost of sales mean?
Reflects the direct costs associated with the manufacturing, packaging, and distribution of a specific pharmaceutical product. This includes raw material procurement, labor costs for production, and logistics expenses required to bring the drug to market. Monitoring this helps assess the efficiency of the supply chain and production processes for the specific therapeutic.